## WE CLAIM:

- 1 1. A pharmaceutical composition comprising:
- a) from about 0.1% to about 50 % by weight of lamotrigine or acid addition salt thereof;
- b) from about 15.5% to about 70% by weight of microcrystalline cellulose;
- from about 0.1% to about 14.5% by weight of sodium starch glycolate; and from about 0.1%
- 7 to about 4.5% by weight of polyvinylpyrrolidone.
- 1 2. The pharmaceutical composition according to claim 1, further comprising from about
- 2 0.1% to about 14.5% by weight of lactose.
- 1 3. The pharmaceutical composition according to claim 1, wherein the composition
- 2 comprises about 17% to about 70% by weight of microcrystalline cellulose, about 0.1% to
- 3 about 13% by weight of sodium starch glycolate, and about 0.1% to about 4% by weight of
- 4 polyvinylpyrrolidone.
- 1 4. The pharmaceutical composition according to claim 2, wherein the composition
- 2 comprises about 17% to about 70% by weight of microcrystalline cellulose, about 0.1% to
- 3 about 13% by weight of sodium starch glycolate, about 0.1% to about 4% by weight of
- 4 polyvinylpyrrolidone, and about 0.1% to about 13% by weight of lactose.
- 1 5. The pharmaceutical composition according to claim 2, wherein the composition
- 2 comprises about 20% to about 70% by weight of microcrystalline cellulose, about 0.1% to
- 3 about 10% by weight of sodium starch glycolate, about 0.1% to about 3% by weight of
- 4 polyvinylpyrrolidone, and about 0.1% to about 10% by weight of lactose.
- 1 6. The pharmaceutical composition according to claim 1, wherein the sodium starch
- 2 glycolate is intragranular.
- 1 7. The pharmaceutical composition according to claim 1, wherein the sodium starch
- 2 glycolate is extragranular.

1 8. The pharmaceutical composition according to claim 1, wherein the composition is a

2 tablet.

3

4

5

- 1 9. The pharmaceutical composition according to claim 1, wherein at least 80% by weight
- 2 of the lamotrigine or the acid addition salt thereof dissolves within 10 minutes.
- 1 10. The pharmaceutical composition according to claim 1, wherein at least 90% by weight
- 2 of the lamotrigine or the acid addition salt thereof dissolves within 30 minutes.
- 1 11. The pharmaceutical composition according to claim 1, wherein the composition is
- 2 stable after three months storage at 40°C and 75% RH with at least 98% of the lamotrigine or
- 3 acid addition salt thereof remaining after three months.
- 1 12. A process for preparing a pharmaceutical composition, the process comprising wet
- 2 granulating a composition that includes:
  - a) from about 0.1% to about 50 % by weight of lamotrigine or acid addition salt thereof;
    - b) from about 15.5% to about 70% by weight of microcrystalline cellulose;
- 6 c) from about 0.1% to about 14.5% by weight of sodium starch glycolate; and
- 7 d) from about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.
- 1 13. The process according to claim 12, wherein the pharmaceutical composition further
- 2 comprises from about 0.1% to about 14.5% by weight of lactose.
- 1 14. The process according to claim 12, wherein the composition comprises about 17% to
- 2 about 70% by weight of microcrystalline cellulose, about 0.1% to about 13% by weight of
- 3 sodium starch glycolate, and about 0.1% to about 4% by weight of polyvinylpyrrolidone.
- 1 15. The process according to claim 13, wherein the composition comprises about 17% to
- 2 about 70% by weight of microcrystalline cellulose, about 0.1% to about 13% by weight of
- 3 sodium starch glycolate, about 0.1% to about 4% by weight of polyvinylpyrrolidone, and
- 4 about 0.1% to about 13% by weight of lactose.
- 1 16. The process according to claim 13, wherein the composition comprises about 20% to
- 2 about 70% by weight of microcrystalline cellulose, about 0.1% to about 10% by weight of
- 3 sodium starch glycolate, about 0.1% to about 3% by weight of polyvinylpyrrolidone, and
- 4 about 0.1% to about 10% by weight of lactose.

1 17. The process according to claim 11, wherein the pharmaceutical composition comprises

- 2 about 50% by weight of lamotrigine, about 20% to about 30% by weight of microcrystalline
- 3 cellulose, about 10% to about 14.5% by weight of lactose, about 4% to about 10% by weight
- 4 of sodium starch glycolate and about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.
- 1 18. The process according to claim 12 or 13, wherein the lamotrigine or its acid addition
- 2 salt, microcrystalline cellulose, sodium starch glycolate, polyvinylpyrrolidone and/or lactose
- 3 are blended and then granulated with water.
- 1 19. The process according to claim 12 or 13, wherein the lamotrigine or its acid addition
- 2 salt, microcrystalline cellulose, sodium starch glycolate and/or lactose are blended and then
- 3 granulated with an aqueous solution of polyvinylpyrrolidone.
- 1 20. The process according to claim 18, further comprising screening the wet mass to
- 2 obtain granules.
- 1 21. The process according to claim 19, further comprising screening the wet mass to
- 2 obtain granules.
- 1 22. The process according to claim 20, further comprising drying and sieving the granules.
- 1 23. The process according to claim 21, further comprising drying and sieving the granules.
- 1 24. The process according to claim 22, further comprising compressing the granules to
- 2 form tablets.
- 1 25. The process according to claim 23, further comprising compressing the granules to
- 2 form tablets.
- 1 26. The process according to claim 12, wherein the sodium starch glycolate is
- 2 intragranular.
- 1 27. The process according to claim 12, wherein the sodium starch glycolate is
- 2 extragranular.

1	28. A method of treating a medical condition responsive to lamotrigine, the method	
2	comprises administering a pharmaceutical composition of lamotrigine, the composition	
3	comprising:	
4	(a)	from about 0.1% to about 50% by weight of lamotrigine or acid
5		addition salt thereof;
6	(b)	from about 15.5% to about 70% by weight of microcrystalline
7		cellulose;
8	(c)	from about 0.1% to about 14.5% by weight of sodium starch glycolate
9		and
10	(d)	from about 0.1% to about 4.5% by weight of polyvinylpyrrolidone.

1 29. The method according to claim 28, wherein the pharmaceutical composition further comprises from about 0.1% to about 14.5% by weight of lactose.